Clinical Trial

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-08
notable Trial sites reduced: 134 -> 127 locations 2026-04-08
Trial Details
NCT Number NCT07104383
Lead Sponsor Viking Therapeutics, Inc.
Conditions Weight Loss
Enrollment 1,100 participants
Start Date 2025-06-23
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-07